home / stock / ruby / ruby news

RUBY News and Press, Rubius Therapeutics Inc. From 11/14/19

Stock Information
Company Name: Rubius Therapeutics Inc.
Stock Symbol: RUBY
Market: OTC
Website: rubiustx.com
Menu
RUBY RUBY Quote RUBY Short RUBY News RUBY Articles RUBY Message Board
Get RUBY Alerts

News, Short Squeeze, Breakout and More Instantly...
RUBY - Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity

Aravive's Reverse Merger Path to Public Company Creates Potentially Compelling Overlooked and Underfollowed Investment Opportunity If a company chooses to go public through a reverse merger instead of the more conventional IPO path, it has a higher chance to become an Overlooked and Underf...
RUBY - Rubius Therapeutics EPS misses by $0.03

Rubius Therapeutics (NASDAQ: RUBY ): Q3 GAAP EPS of -$0.59 misses by $0.03 . More news on: Rubius Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

RUBY - Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress

CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today reported third quarter 2019 financial results ...

RUBY - Rubius Therapeutics to Participate in Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced today that Pablo J. Cagnoni, M.D., ch...
RUBY - Rubius Therapeutics Appoints Maiken Keson-Brookes as Chief Legal Officer and Corporate Secretary

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Maiken Keson-Broo...

RUBY - Rubius Therapeutics Highlights Preclinical Oncology Data at Society for Immunotherapy of Cancer Annual Meeting and AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the Company presented preclini...

RUBY - Rubius Therapeutics to Announce Third Quarter 2019 Financial Results

CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced plans to report third quarter 2019 f...
RUBY - Entrada Therapeutics Appoints Nathan Dowden as Chief Operating Officer

BOSTON , Nov. 4, 2019 /PRNewswire/ -- Entrada Therapeutics, a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced the appointment of Nathan J. Dowden as Chief Operating Officer. Mr. D...

RUBY - Rubius Therapeutics Announces Oncology Poster Presentations at Upcoming Medical Conferences

CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present precl...

RUBY - BioMarin readies study of gene therapy for PKU

BioMarin Pharmaceutical ( BMRN -0.5% ) has submitted an application to UK regulators seeking signoff to launch a Phase 1/2 clinical trial evaluating a single administration of BMN 307 in patients with phenylketonuria (PKU), a rare inborn error of metabolism that causes the amino acid phe...
Previous 10 Next 10